(Q36728805)

15 August 2017

1 reference

title

Use of attenuated bacteria as delivery vectors for DNA vaccines (English)

1 reference

15 August 2017

Damini Daudel

1

1 reference

15 August 2017

Gerald Weidinger

series ordinal

2

1 reference

15 August 2017

Simone Spreng

series ordinal

3

1 reference

15 August 2017

publication date

1 February 2007

1 reference

Expert Review of Vaccines

15 August 2017

published in

1 reference

15 August 2017

volume

6

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

97-110

1 reference

Immunization without needles

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

DNA vaccines: successes and limitations in cancer and infectious disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Experience with registered mucosal vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Isolation and Characterization of Gal E Mutant Ty 21a of Salmonella typhi: A Candidate Strain for a Live, Oral Typhoid Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in adult Vietnamese volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Bactofection of mammalian cells by Listeria monocytogenes: improvement and mechanism of DNA delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Comparison of different live vaccine strategies in vivo for delivery of protein antigen or antigen-encoding DNA and mRNA by virulence-attenuated Listeria monocytogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Bacteria as DNA vaccine carriers for genetic immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Bacterial gene therapy strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Mucosal DNA vaccination with highly attenuated Shigella is superior to attenuated Salmonella and comparable to intramuscular DNA vaccination for T cells against HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Comparative analysis using a mouse model of the immunogenicity of artificial VLP and attenuated Salmonella strain carrying a DNA-vaccine encoding HIV-1 polyepitope CTL-immunogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Induction of protective cellular immunity against Mycobacterium tuberculosis by recombinant attenuated self-destructing Listeria monocytogenes strains harboring eukaryotic expression plasmids for antigen 85 complex and MPB/MPT51

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Novel bacterial delivery system with attenuated Salmonella typhimurium carrying plasmid encoding Mtb antigen 85A for mucosal immunization: establishment of proof of principle in TB mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Can a 'flawless' live vector vaccine strain be engineered?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Regulation of host immune responses by modification of Salmonella virulence genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Effect of different plasmids on colonization of mouse tissues by the aromatic amino acid dependent Salmonella typhimurium SL 3261.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

In vitro and in vivo stability of recombinant plasmids in a vaccine strain of Salmonella enterica var. Typhimurium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Plasmid maintenance systems suitable for GMO-based bacterial vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

DNA vaccines: improving expression of antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Functional transfer of eukaryotic expression plasmids to mammalian cells by Listeria monocytogenes: a mechanistic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

An autologous oral DNA vaccine protects against murine melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Gene delivery by attenuated Salmonella typhimurium: comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Oral DNA vaccination: antigen uptake and presentation by dendritic cells elicits protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Vaccination with minigenes encoding for novel 'self' antigens are effective in DNA-vaccination against neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

DNA vaccines designed to inhibit tumor growth by suppression of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

T cell-mediated suppression of angiogenesis results in tumor protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Targeting tumor-associated macrophages as a novel strategy against breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Oral cytokine gene therapy against murine tumor using attenuated Salmonella typhimurium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Combined therapy with flk1-based DNA vaccine and interleukin-12 results in enhanced antiangiogenic and antitumor effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

In vivo correction of genetic defects of monocyte/macrophages using attenuated Salmonella as oral vectors for targeted gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Cloning and characterization of a p53 and DNA damage down-regulated gene PIQ that codes for a novel calmodulin-binding IQ motif protein and is up-regulated in gastrointestinal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Live bacterial vaccines--a review and identification of potential hazards

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Biosafety evaluation of recombinant live oral bacterial vaccines in the context of European regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Vaccine-induced autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.97

21 January 2018

Identifiers

DOI

10.1586/14760584.6.1.97

1 reference

15 August 2017

1 reference